Sign In
Buy AVEO
$15.00
+0 (+0%)
At Close: Apr 18, 2023
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
07:00am, Friday, 16'th Apr 2021
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company's
AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
04:01pm, Friday, 26'th Mar 2021
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the f
AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock
10:32pm, Tuesday, 23'rd Mar 2021
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the
Can AVEO (AVEO) Run Higher on Strong Earnings Estimate Revisions?
08:54am, Friday, 19'th Mar 2021
AVEO (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
AVEO: Drug Approved, But Still A Long Way To Go Before Self Sufficiency
10:34am, Wednesday, 17'th Mar 2021
AVEO: Drug Approved, But Still A Long Way To Go Before Self Sufficiency
AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Lags Revenue Estimates
06:11pm, Tuesday, 16'th Mar 2021
AVEO (AVEO) delivered earnings and revenue surprises of -15.79% and -70.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update
04:05pm, Tuesday, 16'th Mar 2021
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update. “The U.S. Food and Drug Administratio
AVEO Collaborates with Bristol Myers to Conduct Combo Study
03:31pm, Monday, 15'th Mar 2021
AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.
AVEO Pharmaceuticals, CANbridge AV-203 Licensing Deal Axed, AVEO Regains Ex-North American Rights
10:41am, Monday, 15'th Mar 2021
AVEO Pharmaceuticals Inc's (NASDAQ: AVEO) brief positive news of getting FDA approval for Tivozanib in relapsed kidney cancer this month was upset after its partner CANbridge Life Sciences volunt
AVEO Stock Price Increases Over 5% Pre-Market: Why It Happened
08:06am, Friday, 12'th Mar 2021
The stock price of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) has increased by over 5% pre-market. This is why it happened.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA® (tivo
Aveo Pharmaceuticals Stock Volatile After FDA Approval: Technical Levels To Watch
12:15pm, Thursday, 11'th Mar 2021
Aveo Pharmaceuticals Inc. (NASDAQ: AVEO) shares are trading higher Thursday after the company received FDA approval for Fotivda for the treatment of adult patients with relapsed or refractory advanced
Aveo extends gains to 106% after drug maker wins FDA approval for kidney cancer treatment (AVEO)
09:15am, Thursday, 11'th Mar 2021
Shares of Aveo climbed 17% early Thursday, stretching their run higher after the company won US regulatory approval for its renal cancer treatment Fotivda. The stock on Wednesday soared 89% and was su
Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer
08:21am, Thursday, 11'th Mar 2021
The FDA has finally approved AVEO Pharmaceuticals Inc's (NASDAQ: AVEO) tivozanib for advanced renal cell carcinoma, nine years after it first submitted its marketing application to the agency. The
AVEO Stock Price Increases Over 20% Pre-Market: Why It Happened
07:47am, Thursday, 11'th Mar 2021
The stock price of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) has increased by over 20% pre-market. This is why it happened.
